Most drugs approved for multiple sclerosis work by dialling down the immune system. Quantum BioPharma's Lucid-MS targets something else: the enzyme that strips the protective myelin sheath from nerve fibres. On August 10, the FDA cleared the company to test that approach in MS patients for the first time.
The FDA's approval of Quantum's Investigational New Drug application — a submission the company's CEO described as approximately 15,000 pages — clears Lucid-MS for a Phase 2 trial in progressive MS. Phase 2 is the stage that tests actual efficacy, not just safety. Prior Phase 1 trials were run in healthy volunteers and found the drug well tolerated, according to an August 10 press release filed with the SEC.
Lucid-MS is designed to inhibit protein arginine deiminase 2, or PAD2 — an enzyme the company says drives myelin degradation, the process at the root of disability progression in MS. Most approved therapies try to slow the immune system's attack on myelin; this drug is designed to protect myelin directly, according to the company. That distinction matters most in progressive MS, where immune-targeting drugs have had limited reach and treatment options remain narrow.
Shares closed at $3.80 on August 14, up 17.65% from the previous close of $3.23. Dollar volume was about $1.0 million across 2,244 trades. The free float is about 3.5 million shares. Short volume on the session was 54,732 shares, 40.17% of reported volume.
The trial will be randomized, double-blind and placebo-controlled, and will measure both clinical and radiological markers of disease progression. Site selection is already underway, and Quantum is working with a global clinical research organisation whose name it did not disclose. Patient enrolment timing was not given.
Quantum held about $9.5 million in combined cash and digital assets as of June 30, and management says the current burn rate — operating expenses ran roughly 53% lower than a year earlier in the second quarter — gives the company a runway to at least October 2027. In animal models, Lucid-MS both prevented and reversed myelin breakdown, the company says. The Phase 2 trial will be the first test of whether it does the same in people.